Tag Archives: ML8500

Light-induced cytotoxicity in cells utilizing an automated well plate illuminator

March 7, 2023 by Modulight
No comments
Presented in: SPIE BIOS 2023 Authors: Laura Vesala, Robert Perttilä, Elias Kokko, Johannes Kivelä, Lasse Orsila, Petteri Uusimaa    Presented in: SPIE BIOS 2023 Authors: Laura Vesala, Robert Perttilä, Elias Kokko, Johannes Kivelä, Lasse Orsila, Petteri Uusimaa   Delivering therapeutic drug molecules to the target site and releasing the cargo site-specifically is of major interest in biomedicine. To carry and release drugs to specific target tissues, different nanotechnology approaches have been utilized. These include light-sensitive liposomal carriers, which have been engineered to release cargo from their aqueous cores when illuminated by certain wavelengths of laser light. To study drug release parameters in vitro, Modulight Continue reading →

A Non-Invasive Deep Photoablation Technique to Inhibit DCIS Progression and Induce Antitumor Immunity

November 23, 2022 by Modulight
No comments
Published in: Cancers Authors: Kensuke Kaneko, Hiroshi Nagata, Xiao-Yi Yang, Joshua Ginzel, Zachary Hartman, Jeffrey Everitt, Philip Hughes, Timothy Haystead, Michael Morse, Herbert Kim Lyerly, Takuya Osada    Published in: Cancers Authors: Kensuke Kaneko, Hiroshi Nagata, Xiao-Yi Yang, Joshua Ginzel, Zachary Hartman, Jeffrey Everitt, Philip Hughes, Timothy Haystead, Michael Morse, Herbert Kim Lyerly, Takuya Osada   The study investigated HSP90-targeted PDT for minimally invasive treatment of ductal carcinoma in situ (DCIS), benign breast cancer condition that has potential to progress into breast cancer. PDT with ML8500 combined to ML7710 resulted in effective in vitro cytotoxicity and with ML7710 in vivo, which was further potentiated with PD-L1 immune checkpoint inhibitors.   Read the article Continue reading →

Development of heat shock protein 90-targeted PDT for inflammatory breast cancer

May 17, 2021 by Modulight Content
No comments
Motivation of the study In photodynamic therapy (PDT), systemically administered photosensitizer is activated within the tumor using focused near-infrared light, typically a laser with a wavelength matching the absorption peak of the photosensitizer. Several photosensitizers have been clinically approved for the treatment of different cancers; however, their accumulation is non-tumor exclusive which exposes healthy tissues to side effects like daylight-induced phototoxicity. A promising strategy to improve tumor selectivity is to couple photosensitizer to a tumor-targeting agent that binds to a specific antigen expressed on the Continue reading →Customer case Research by: Duke University, founded in 1924, is one of the leading and wealthiest private research universities in the USA. The most notable Duke alumni is President Richard Nixon. Research at Duke University has been awarded with several Nobel prizes in recent years for groundbreaking discoveries in biochemistry and medicine, such as G-protein coupled receptors, DNA mismatch repair, and cellular regulation of hypoxia. Modulight products: ML8500, ML7710 (665 nm, 689 nm, 750 nm) Laser use: Heat shock protein 90-targeted PDT for breast cancer Continue reading →

In vitro illumination using ML8500: osmium-based anticancer photosensitizer with highest hypoxic activity reported to date

March 26, 2021 by Modulight Content
No comments
  Study protocol to determine wavelength, fluence, and irradiance activities of Os-4T:   Key observations Illumination parameters significantly affected the phototoxicity of Os-4T. The green light (525 nm) was more effective than the red light (630 nm) at lower fluences, while the maximal potency was achieved at both wavelengths when using fluences higher than 100 J/cm2. Irradiance affected the potency with both the red and the green light that were more effective when lower irradiances were used.   Graphs from the original publication. Open-access content Continue reading →Basic Info of the Study Research by: University of Texas at Arlington, US. One of the leading groups in photoactive drug discovery. Developed first clinical-level rubidium-based PS (TLD-1433), now in Theralase-sponsored Phase 2 trials for bladder cancer. Modulight products: ML8500 (445 nm, 525 nm, 630 nm, 753 nm, 810 nm) Laser use: Photoactive drug discovery Link to the study: Dr. Sherri McFarland (see her referral of Modulight) Research topics: Medicinal inorganic chemistry and drug discovery. Special interest in the synthesis of novel transition metal complexes and Continue reading →

Near-infrared Absorbing Ru(II) Complexes Act as Immunoprotective Photodynamic Therapy (PDT) Agents Against Aggressive Melanoma

September 9, 2020 by Modulight
No comments
Published in: Chemical Science Authors: Liubov M. Lifshits, A. Roque III, Prathyusha Konda, Susan Monro, Houston D. Cole, David von Dohlen, Susy Kim, Gagan Deep, Randolph P. Thummel, Colin G. Cameron, Shashi Gujar, Sherri A. McFarland    Published in: Chemical Science Authors: Liubov M. Lifshits, A. Roque III, Prathyusha Konda, Susan Monro, Houston D. Cole, David von Dohlen, Susy Kim, Gagan Deep, Randolph P. Thummel, Colin G. Cameron, Shashi Gujar, Sherri A. McFarland   9 novel Ru-based coordination complexes with different ligands were systematically synthetized and explored with aim to long wavelengths (>700 nm – >1000 nm depending on the compound) and high singlet oxygen quentum yeild for melanoma PDT. Light dosimetry and phototoxicities were studied in vitro (ML8500) and in vivo. Continue reading →

Breaking the barrier: an osmium photosensitizer with unprecedented hypoxic phototoxicity for real world photodynamic therapy

August 3, 2020 by Modulight
No comments
Published in: Chemical Science Authors: John A. Roque III, Patrick C. Barrett, Houston D. Cole, Liubov M. Lifshits, Ge Shi, Susan Monro, David von Dohlen, Susy Kim, Nino Russo, Gagan Deep, Colin G. Cameron, Marta E. Alberto, Sherri A. McFarland    Published in: Chemical Science Authors: John A. Roque III, Patrick C. Barrett, Houston D. Cole, Liubov M. Lifshits, Ge Shi, Susan Monro, David von Dohlen, Susy Kim, Nino Russo, Gagan Deep, Colin G. Cameron, Marta E. Alberto, Sherri A. McFarland   ML8500 was used for specialized dosimetry studies in the development of the osmium-based PS using similar drug development strategy as for the analogous Ru(II) series that resulted in TLD1433 (first metal complex in clinical trials). The Os-compound approaches the ideal properties with multi-wavelength activation Continue reading →

Heat shock protein 90-targeted photodynamic therapy enables treatment of subcutaneous and visceral tumors

May 8, 2020 by Modulight
No comments
Published in: Communications Biology Authors: Kensuke Kaneko, Takuya Osada, Michael A. Morse, William R. Gwin, Joshua D. Ginzel, Joshua C. Snyder, Xiao-Yi Yang, Cong-Xiao Liu, Márcio A. Diniz, Khaldon Bodoor, Philip F. Hughes, Timothy AJ. Haystead, H. Kim Lyerly    Published in: Communications Biology Authors: Kensuke Kaneko, Takuya Osada, Michael A. Morse, William R. Gwin, Joshua D. Ginzel, Joshua C. Snyder, Xiao-Yi Yang, Cong-Xiao Liu, Márcio A. Diniz, Khaldon Bodoor, Philip F. Hughes, Timothy AJ. Haystead, H. Kim Lyerly   ML7710 was used for in vivo and ML8500 coupled to ML7710 for in vitro studies of HSP90-targeted verteporfin PDT for breast cancer. This strategy has both diagnostic and therapeutic potential across all breast cancer subtypes found up to few cm in depth, and may provide Continue reading →

Fully automated illumination study series for modern cancer drug development

November 9, 2016 by Modulight Content
No comments
Fully automated illumination study series for modern cancer drug development In vitro cell viability and dose escalation study for developing photosensitive or photoactivated drugs using Modulight ML7710 medical laser and ML8500 automated illumination system.     Experimental set up        Fully automated illumination study series for modern cancer drug development In vitro cell viability and dose escalation study for developing photosensitive or photoactivated drugs using Modulight ML7710 medical laser and ML8500 automated illumination system.   STUDY PLAN The goal was to investigate the effect of irradiance and light dose on a cancer cell line while keeping the photosensitive drug dosing constant. The well-by-well dose escalation plan was done in tabular format. TARGET Cancer cell line incubated at 37°C in acidic culture DRUG TYPE Photosensitive or Continue reading →